6 The phosphodiesterase-five inhibitor sildenafil is accredited for PAH in FC I–IV in the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) such as bosentan, sitaxentan and ambrisentan are oral therapies accredited for use in PAH. As no oral agent has revealed superiority there stays debate as to which need to be mad